trans-Stilbenoids: potent and selective inhibitors for human cytochrome P450 1B1
暂无分享,去创建一个
Sun Choi | Y. Chun | Sanghee Kim | Chaemin Lim | Ji Min Lee | Jin Hee Lee | S. Ohk
[1] T. Itoh,et al. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. , 2010, Bioorganic & medicinal chemistry.
[2] R. Dahiya,et al. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. , 2009, Cancer research.
[3] O. Hankinson,et al. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[4] N. Roodi,et al. Estrogen Metabolism and Breast Cancer , 2009, Annals of the New York Academy of Sciences.
[5] V. Vasiliou,et al. Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.
[6] R. D. Bruno,et al. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. , 2007, Bioorganic & medicinal chemistry.
[7] G. Fuller,et al. Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target , 2007, Clinical Cancer Research.
[8] C David Stout,et al. Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.
[9] W. Baer-Dubowska,et al. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. , 2007, Molecular nutrition & food research.
[10] D. Nebert,et al. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.
[11] Thomas K. H. Chang,et al. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. , 2006, Toxicology and applied pharmacology.
[12] Y. Moon,et al. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[13] A. Sparreboom,et al. Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention , 2006, Molecular Cancer Research.
[14] Y. Chun,et al. MODULATION OF HUMAN CYTOCHROME P450 1B1 EXPRESSION BY 2,4,3′,5′-TETRAMETHOXYSTILBENE , 2005, Drug Metabolism and Disposition.
[15] G. Murray,et al. Cytochrome P450 1B1: a novel anticancer therapeutic target. , 2005, Future oncology.
[16] R. Dahiya,et al. Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer , 2005, Clinical Cancer Research.
[17] N. Seeram,et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.
[18] G. Murray,et al. Cytochrome P450 enzymes: novel options for cancer therapeutics. , 2004, Molecular cancer therapeutics.
[19] T. Shimada,et al. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.
[20] Y. Chun,et al. Discovery of cytochrome P450 1B1 inhibitors as new promising anti‐cancer agents , 2003, Medicinal research reviews.
[21] Tsutomu Shimada,et al. Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. , 2003, Chemico-biological interactions.
[22] T. Shimada,et al. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. , 2003, Mutation research.
[23] A. Luch,et al. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. , 2002, Chemical research in toxicology.
[24] L. Leung,et al. Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[25] Y. Chun,et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. , 2002, Journal of medicinal chemistry.
[26] F. Guengerich,et al. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.
[27] H. McLeod,et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer , 2001, British Journal of Cancer.
[28] T. Chang,et al. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. , 2000, Canadian journal of physiology and pharmacology.
[29] F. Guengerich,et al. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.
[30] T. Shimada,et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.
[31] J. Ward,et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] J A McKay,et al. Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.
[33] N. Walker,et al. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. F. Greenlee,et al. Expression of cytochrome P450 CYP1B1 in breast cancer , 1995, FEBS letters.
[35] T. Shimada,et al. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.